Marvin A. Soriano-Ursúa
◽
Eunice D. Farfán-García
◽
Simonetta Geninatti-Crich
Background:
Despite the historical employment of boron-containing compounds
(BCCs) with medicinal purposes, the reported cases of BCC toxicity in humans during the
twentieth-century drived us towards a “boron-withdrawal” period. Fortunately, the use of boric
acid for specific purposes remains, and the discovery of natural BCCs with biological action
attractive for therapeutic purposes as well as the introduction of some new BCCs for
clinical use has reactivated the interest in studying the properties of these BCCs.
Methods:
We carried out a structured search of bibliographic databases for scientific peerreviewed
research literature regarding boron toxicity and linked that information to that of
BCCs in drug design and development. A deductive qualitative content analysis methodology
was applied to analyse the interventions and findings of the included studies using a theoretical
outline.
Results:
This review recapitulates the following on a timeline: the boron uses in medicine, the
data known about the toxicological profiles of some BCCs, the pharmacological properties of
some BCCs that are employed in cancer and infectious disease therapies, and the known
properties of BCCs recently introduced into clinical assays as well as the identification of
their structure-activity relationships for toxicity and therapeutic use. Then, we discuss the use
of new approaches taking advantage of some toxicological data to identify potent and efficient
BCCs for prevention and therapy while limiting their toxic effects.
Conclusion:
Data for boron toxicity can be strategically used for boron-containing drug design.